Altamira Therapeutics Ltd. (CYTO) |
|
2.77 -0.46 (-14.24%)
|
01-27 15:59 |
|
Open: |
3.05 |
Pre. Close: |
3.23 |
|
High:
|
3.07 |
Low:
|
2.7 |
|
Volume:
|
174,852 |
Market Cap:
|
4(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:41 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 5.51  One year: 6.97 |
| Support: |
Support1: 2.7 Support2: 2.24 |
| Resistance: |
Resistance1: 4.72 Resistance2: 5.96 |
| Pivot: |
4.63 |
| Moving Average: |
MA(5): 3.56 MA(20): 4.79
MA(100): 5.78 MA(250): 11.23 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 10 %D(3): 15.7 |
| RSI: |
RSI(14): 25 |
| 52-week: |
High: 43 Low: 0.49 |
| Average Vol(K): |
3-Month: 44 (K) 10-Days: 93 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CYTO ] has closed below the lower bollinger band by 3.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CYTO ] is to continue within current trading range. It is unclear right now based on current values. 41.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.09 - 3.12 |
3.12 - 3.14 |
|
Low:
|
2.64 - 2.68 |
2.68 - 2.7 |
|
Close:
|
2.73 - 2.79 |
2.79 - 2.82 |
|
Company Description |
|
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda. |
Headline News |
Fri, 27 Jan 2023
Is Altamira Therapeutics Ltd (CYTO) Stock a Smart Investment Friday? - InvestorsObserver
Fri, 27 Jan 2023
Healthcare Stocks Moving Friday: QNCX, NAMS, HARP, ICVX, NMRD, KERN, CYAD, CYTO - InvestorsObserver
Fri, 27 Jan 2023
CYTO stock falls amid plans to increase share capital (NASDAQ ... - Seeking Alpha
Tue, 24 Jan 2023
CYTO Craters after COVID-19 Drug Flub - TipRanks
Tue, 24 Jan 2023
Altamira: NASAR Interim Analysis Shows Superior Efficacy Of ... - RTTNews
Thu, 19 Jan 2023
Soluble cyclase-mediated nuclear cAMP synthesis is sufficient for ... - pnas.org
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
1 (M) |
|
% Held by Insiders
|
992160 (%) |
|
% Held by Institutions
|
7 (%) |
|
Shares Short
|
23 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.657e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
289.7 |
|
Return on Equity (ttm)
|
-49.2 |
|
Qtrly Rev. Growth
|
1.29e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-80.79 |
|
EBITDA (p.s.)
|
-1.3625e+006 |
|
Qtrly Earnings Growth
|
-1.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.04 |
|
Price to Cash Flow
|
0.49 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
21570 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-04-30 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
